Navigation Links
EntreMed To Raise $10.7 Million In Registered Direct Offering
Date:3/1/2013

ROCKVILLE, Md., March 1, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced today that it has received commitments from investors, including institutional investors Kleiner Perkins Caufield Byers China Fund II, L.P. and IDG-Accel China Growth Fund III L.P. to purchase approximately $10.7 million of securities in a registered direct offering.  EntreMed expects to receive net proceeds of approximately $10.3 million after deducting agent's fees and other offering expenses.  EntreMed has agreed to sell an aggregate of 4,495,833 shares of its common stock and warrants to purchase 2,247,917 shares of its common stock.  Each unit, consisting of one share of common stock and a warrant to purchase 0.5 share of common stock will be sold for a purchase price of $2.40.  The warrants will become exercisable 181 days after the closing and have a term of three years and an exercise price equal to the market value per share of common stock on February 28, 2013.  The offering is expected to close on or about March 6, 2013, subject to satisfaction of customary closing conditions.

(Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO)

"We are very pleased to have the support of this group of strategic investors.  We intend to use the net proceeds from this offering to advance our clinical development plan, including additional trials for ENMD-2076, and for general corporate purposes," said Dr. Ken Ren , the Company's Chief Executive Officer.

Burrill Securities LLC acted as exclusive placement agent in this transaction.  A shelf registration statement containing a prospectus relating to the shares of common stock an
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Reports First Quarter 2012 Financial Results
2. EntreMed Announces Initiation Of Phase 2 Trial In Triple-negative Breast Cancer
3. EntreMed Reports Second Quarter 2012 Financial Results
4. Dana-Farber Cancer Institutes Ursula A. Matulonis, MD Article on EntreMeds ENMD-2076 Published in the European Journal of Cancer
5. EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
6. PNAS Publishes Preclinical Results of EntreMeds 2ME2 for Multiple Sclerosis
7. EntreMed Announces Initiation Of Phase 2 Trial In Advanced/Metastatic Soft Tissue Sarcoma
8. Evergreen Healthcare Foundation Gala Raises Nearly $1.1 Million to Benefit Breast Health Center
9. Xtelligent Media Raises $800K in Funding and Launches EHRintelligence.com
10. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
11. BHI Raises Awareness of Hearing Aids as Potential Therapy to Help Quiet "Ringing in the Ears" During National Tinnitus Awareness Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 /PRNewswire/ ... biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for ... need and commercial potential, today announced that it ... shares of its common stock and Series C ... stock.  Funds under the management of QVT Financial ...
(Date:12/24/2014)... -- ResMed (NYSE: RMD ) today announced its ... device manufacturer BMC Medical Co., Ltd. The ... below infringe ResMed,s patents, and entered an order prohibiting BMC ... the United States : , iVolve nasal ... nasal pillows mask , iVolve full face mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... YORK, Feb. 9, 2012 Just weeks after winning ... behalf of Novartis Pharmaceuticals Sales Representatives, Attorneys from Sanford ... complaint in the U.S. District Court for the Southern ... Sales Representatives and other similarly-situated employees at LEO Pharma ...
... Resource Anesthesia , an anesthesia contract management company based ... its management portfolio. Phil Haynie, MBA, MSN, ... company has added the following facilities to its roster ... -- Hadley, 4601 Martin Luther King Jr. Avenue S.W., ...
Cached Medicine Technology:Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court 2Leo Pharma Sales Reps File Overtime Class Action in New York Federal Court 3Resource Anesthesia Adds Locations Under Management, Announces Addition of HealthStream LearningCenter® 2
(Date:12/24/2014)... (PRWEB) December 25, 2014 Epigenetics finds ... science research, including oncology, drug discovery, developmental biology, and ... emerging as one of the most widely used techniques ... to GLOBOCAN, the prevalence of cancer is rapidly growing ... cases, 8.2 million cancer deaths, and 32.6 million people ...
(Date:12/24/2014)... York, New York (PRWEB) December 24, 2014 ... to mount in a mass tort litigation currently underway ... LLP reports. As of December 24, 2014, court ... the proceeding on behalf of individuals who developed gynecomastia ... its use. Data from the Court indicates that this ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... http://www.xareltolawsuit2015.com/ ) that allege the blood thinner caused ... has outlined a leadership structure for the proceeding, ... dated December 17th, the Court plans to select ... parties and also plans on appointing a Plaintiffs’ ...
(Date:12/24/2014)... TX (PRWEB) December 25, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. Stivarga is a drug which is used ... drug is orally administered and is also prescribed to ... drug which is FDA approved is a multi-kinase inhibitor ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter ... who have abstained from sex for one year will be allowed ... policy that would reverse a 31-year ban on donations from men ... Administration announced Tuesday its intention to release a new draft guidance ... donations from gay men. The FDA is changing its policy ...
Breaking Medicine News(10 mins):Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3
... , Diabetes: A Deeper Look ... , DETROIT, Dec. 3 In the United States, a ... the Detroit Science Center will debut its newest exhibit, Diabetes: A ... about diabetes, diabetes treatment and the role insulin plays in the body. ...
... , WASHINGTON, Dec. 3 The Redwood Gazette ... struggling financially and worried about paying for their medicines. The ... more than 6 million patients find programs providing prescription medicines for ... has access to information on more than 475 patient assistance programs, ...
... in solid organ transplants have been issued with expert advice ... the global H1N1 (swine flu) pandemic. The paper, ... also urges them to stay alert to the significant concerns ... even bird flu (H5N1), to develop into a strain with ...
... compulsive users also feel depressed or anxious when not online ... Chinese adolescents found that teens who are addicted to the ... teens. , The survey of 1,618 students aged 13 ... Guangzhou in Guandong Province found that about 16 percent said ...
... ... of surgical cases on the iPhone or iPod touch. Pop up menu’s and one touch exporting ... provider. , ... I-Surgery , a new iPhone application for surgery, can be used by surgeons, residents, surgical ...
... ... to cheer up children during the holidays with his self-published and illustrated books, “Little ... nationwide. , ... (PRWEB) December 3, 2009 -- Carlton Scott RN , hopes to bring holiday ...
Cached Medicine News:Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:Transplant infectious disease experts provide pandemic guidance 2Health News:Transplant infectious disease experts provide pandemic guidance 3Health News:Teen Internet Addicts More Likely to Self-Harm: Study 2Health News:Traveling Nurse Cheers up Kids with Handmade Books 2Health News:Traveling Nurse Cheers up Kids with Handmade Books 3
... parafollicular C-cells of the thyroid gland and ... action of calcitonin is to lower plasma ... in decreased mobilization of calcium from bone ... conditions associated with high levels of bone ...
... The HeartMate II Left Ventricular Assist System ... pump shown to restore hemodynamic function and ... Through the rotary action of a single-moving ... long-term full circulatory support by pumping blood ...
... the first, easy-to-use, non-invasive diagnostic technology ... cardiac dysfunction including acute heart failure, ... cardiac conditions. Designed to seamlessly fit ... enable clinicians caring for cardiac patients ...
... provides a new screening, diagnostic, treatment assessment ... management of sleep-related breathing disorders. The Watch-PAT ... need for an ambulatory, reliable, patient friendly ... the great number of OSA sufferers, and ...
Medicine Products: